Clinical Study Of The Correlation Between UGT1A1*28 Polymorphism And The Adverse Reaction And The Efficacy Of The Irinotecan Chemotherapy In Patients With Advanced Digestive Tract Malignant Tumors

Objective The objective of this study was to definite the relationship between UGT1A1* 28 polymorphism and the adverse reaction of chemotherapy and efficacy of the irinotecan chemotherapy in patients with advanced digestive tract malignant tumors.Methods The patients who apropriate irinotecan in The Affiliated Tumor Hospital of Guangxi Medical University and The First Affiliated Hospital of Guangxi Medical University from October 2013 to December 2013, will be done the peripheral blood DNA extraction, PCR amplification and sequencing pyrophosphate to detect UGT1A1* 28 gene polymorphism.Observe hematologic toxicity and gastrointestinal adverse reactions of patients in the chemotherapy,and analysis the relationship between UGT1A1* 28 polymorphism and the adverse reaction of chemotherapy and efficacy of the irinotecan chemotherapy in patients with advanced digestive tract malignant tumors.Results Of the 57 case tumor patients who apropriate irinotecan, male 43 cases,14 cases of women, received FOLFIRI regimen in 44 cases, received Irinotecan plus raltitrexed regimen in 11 cases, received Irinotecan plus oxaliplatin regimen in 2cases; forty patients (70.2%) were identified with TA6/TA6 genotype, and seventeen (29.8%) with TA6/TA7 genotype, no TA7/TA7 genotype was found, in the 28th site of UGT1A1 promoter.In patients with wild type and mutant type,10 cases (25%) and 3 cases (17.6%) had grade â…¡-â…£diarrhea; 19 cases (47.5%) and 6 cases (35.3%) had grade â…¡-â…£ leucopenia;19 cases (47.5%) and 5 cases (29.4%) had grade â…¡-â…£neutropenia;12 cases (30%) and 4 cases (23.5%) had grade â…¡-â…£ Hemoglobin reduce;3 cases (7.5%) and 2 cases (11.8%) had grade â…¡-â…£ thrombocytopenia.The response rates among all groups did not statistically differ.17 cases (42.5%) and 5 cases (29.4%)were evaluatedDCR in wild type and mutant type patients,and the two groups did not statistically differ.Conclusion 1. For the irinotecan chemotherapy in patients with advanced digestive tract malignant tumors, the UGT1A1*28 polymophism mutant type did not increased the risk of developing grade â…¡-â…£leucopenia,gradeâ…¡-â…£ Hemoglobin reduce,gradeâ…¡-â…£ thrombocytopenia,grade â…¡-â…£diarrhea, compared with wild type patients.2.There were no significant difference in DCR between UGT1A1 gene mutation type and wild type patients.